ZIVO BIOSCIENCE, INC. (OTCMKTS:ZIVO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03Amendments to the Article of Incorporation or Bylaws; Changes in Fiscal Year

On November 8, 2017, the shareholders of Zivo Bioscience, Inc. approved Articles of Amendment (the “Articles of Amendment”) amending the Company’s Articles of Incorporation to increase the number of the Company’s authorized shares of common stock from 450,000,000 to700,000,000. The Articles of Amendment were filed with the Secretary of State of the State of Nevada on, and effective as of, November 9, 2017. A copy of the Articles of Amendment is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders

At the annual meeting of the shareholders of Zivo Bioscience, Inc. on November 8, 2017, shareholders: (1) elected the five nominees for Board of Directors to serve until the next annual meeting of shareholders in 2017 and until his/her successor is elected and qualified; (2) approved the proposal to amend the Company’s Articles of Incorporation to increase the authorized shares of common stock from 450,000,000 to 700,000,000; and (3) an advisory approval of the named executive officer compensation. The results of the voting are shown below.

Proposal 1 –Election of Directors

Proposal 2 –Increase in Authorization of Shares from 300,000,000 to 450,000,000

Proposal 3 –Advisory approval of the named executive officer compensation

Item 9.01Financial Statements and Exhibits

(d)Exhibits.

3.1Articles of Amendment, as filed with the Secretary of State of the State of Nevada on November 9, 2017.

Zivo Bioscience, Inc. Exhibit
…
To view the full exhibit click here

About ZIVO BIOSCIENCE, INC. (OTCMKTS:ZIVO)

Zivo Bioscience, Inc., formerly Health Enhancement Products, Inc., is a biotechnology company. The Company is engaged in the study, development and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. The Company focuses on research and identification of its bioactive ingredients. It focuses to sell natural bioactive ingredients derived from its algae cultures to animal, human and dietary supplement and medical food manufacturers. It is also engaged in development of biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation. It focuses on developing, manufacturing, marketing and selling tests that allow users to optimize personal health and identify future health risks. The Company manufactures algal products and derivatives, and has various product platforms.